Member Login

Forgot your password?

Logged-In Members: Renew
New Users: Create an Account
 

Cardiac Amyloidosis Resources
 

ImageGuide Registry

See the benefits and how to enroll!
 

Cardiac Amyloidosis


Cardiac Amyloidosis


ASNC is the premier source for education and quality in the rapidly expanding area of cardiac amyloidosis.

Through its initiatives and partnerships, ASNC is supporting a collaborative approach to awareness, early diagnosis, and effective treatments that will save lives and improve the quality of life for patients with CA. Access the latest educational resources and activities including our new app and share with your colleagues! 

NEW
 

NCKSAP: Cardiac Amyloidosis, 1st Edition
Offers 10 CME/MOC CreditsMOC
Expires February 28, 2026



 


Learning Objectives
Upon completion of this module, learner will be able to: 

  • Describe cardiac amyloidosis subtypes and identify symptoms, associated clinical conditions, and typical non-nuclear imaging features.
  • Identify appropriate clinical scenarios for the use of Tc99m-PYP/DPD/HMDP imaging in cardiac amyloidosis.
  • Apply appropriate Tc99m-PYP/DPD/HMDP, I123-MIBG, and SPECT/PET amyloid binding tracer standardized imaging techniques to optimize assessment of cardiac amyloidosis.
  • Interpret and communicate diagnostic and prognostic findings on Tc99m-PYP/DPD/HMDP, I123-MIBG, and SPECT/PET amyloid binding tracers in the assessment of cardiac amyloidosis.


 

NEW Video Series

Bone Scintigraphy for Cardiac Amyloidosis: A four-lecture series of short videos delivered by ASNC Experts


Sponsored by Pfizer, Inc.

 

ASNC has developed Cardiac Amyloidosis OnDemand, a 3-module CME accredited program so you can learn the A-Z's of cardiac amyloidosis to diagnose and treat patients in today's multimodality imaging environment.

This curriculum features content from ASNC's array of amyloid programs curated to meet your needs. Each module contains two video presentations from leading experts discussing the diagnosis, treatment, and management of patients with cardiac amyloidosis.
Earn up to 2.25 CME credits. 

MEMBERS GET FREE ACCESS!

  
 

ASNC Issues Statement on How to Use HMDP in Cardiac Amyloidosis Imaging

Shortages of pyrophosphate (PYP), the radiopharmaceutical most commonly used in the U.S. for noninvasive diagnosis of transthyretin (ATTR) cardiac amyloidosis, should not delay imaging in at-risk patients. Instead, ASNC is guiding imagers to use 99mtechnetium (99mTc)-hydroxymethylene diphosphonate (HMDP or HDP) to ensure patients continue receiving prompt evaluation of, and treatment for, cardiac amyloidosis.


Cardiac Amyloidosis Tools 

Download these posters and our pocket guide from our Think Amyloid project to distribute to your multidisciplinary care team.

Also available in Spanish.

Think Amyloid Primary Care Clinics Poster
Think Amyloid Inpatient Floors Poster
Think Amyloid Cardiology Specialty Clinics Poster
 Think Amyloid Echocardiography Laboratory Poster
 

Cardiac Amyloidosis Flowchart - Exclusive Content for Members!

Access the 11"x17" Cardiac Amyloidosis Flowchart and our Transthyretin Cardiac Amyloidosis: Frequently Asked Questions guide. Not a member? Join ASNC today!

Download our new 11"x17" flowchart designed to guide your clinical assessment of cardiac amyloidosis.
 
 


Transthyretin Cardiac Amyloidosis: Frequently Asked Questions Guide - Exclusive Content for Members!

Download our Transthyretin Cardiac Amyloidosis: Frequently Asked Questions guide. 

 
 
 

Download the Clinical and Quality Resources App

  • Get up-to-date information on cardiac amyloidosis in eight languages: Chinese, English, French, German, Italian, Japanese, Portuguese and Spanish
Topics include:
  • Diagnostic criteria and appropriate imaging utilization in cardiac amyloidosis among others
Hover over the QR code with your camera to download
 
ASNC is uniquely qualified to provide education, information and advocacy that ensures appropriate referrals for Tc-99m PYP imaging; supports high-quality testing, interpretation and reporting of Tc-99m PYP imaging by imagers; and encourages fair reimbursement of Tc-99m PYP services and approval of CA treatment agents.